Abstract :

COVID-19 virus has spread almost all over the world, including Indonesia until now. COVID-19 in people with diabetes mellitus have a risk of exacerbating symptoms. Diabetes is a disease caused by high blood sugar levels. Nanogold has a very strong anti-oxidant capability, while nanosilver has anti-bacterial properties. In this research, nanogold-nanosilver was presented in the form of health drinking water packaged in 1 L bottles and could be consumed directly. This research aimed to determine the effect of nanogold-nanosilver to boost the immunity of people affected by COVID-19 with comorbidities of diabetes mellitus on Jl. Merr Surabaya to Juanda highway, Surabaya City. The method in this research was the lecture method at the beginning of the activity. Health Drinking Water Materials were distributed once a week, namely on Friday, July 31 to August 28, 2020. The sampling technique used accidental sampling with a total sample of 100. Interviews recording medical conditions were collected and analysed. The results obtained were a decrease in blood sugar levels to normal in patients with diabetes mellitus and the immunity of the participant volunteers was well maintained in the midst of the COVID-19 pandemic. The age group under 39 years had the greatest decrease in blood sugar levels. In accordance with the research results, Nanogold-Nanosilver Health Drinking Water has succeeded in increasing and maintaining the immunity of participants who have comorbidities with diabetes mellitus and are affected by COVID-19. Besides, the participant survived not to be affected to COVID-19 during activities.

---

Keywords :

COVID-19, diabetes mellitus, Immunity, nanogold, nanosilver

---

References :

1. C. A. Glass, J. C. Cash, and J. Mullen, “Coronavirus Disease (COVID-19),” in Family Practice Guidelines, New York, NY: Springer Publishing Company, 2020.
2. World Health Organization, “WHO Coronavirus Disease (COVID-19) Dashboard,” 2021. [Online]. Available: https://covid19.who.int/?gclid=CjwKCAjwnK36BRBVEiwAsMT8WJ3y00_BUzvrLsvbl3uthuoTH_Occ45gyEUbpYRyEqAzll3aZB6TYxoCcM0QAvD_BwE. [Accessed: 10-Jan-2021].
3. R. Gupta, A. Ghosh, A. K. Singh, and A. Misra, “Clinical considerations for patients with diabetes in times of COVID-19 epidemic,” Diabetes Metab. Syndr. Clin. Res. Rev., vol. 14, pp. 211–212, 2020, doi: 10.1016/j.dsx.2020.03.002.
4. J. Yang et al., “Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis,” Int. J. Infect. Dis., vol. 94, pp. 91–95, 2020, doi: 10.1016/j.ijid.2020.03.017.
5. World Health Organization, “Diabetes,” 2021. [Online]. Available: https://www.who.int/health-topics/diabetes#tab=tab_1. [Accessed: 12-Jan-2021].
6. World Health Organization, Global Report on Diabetes. France: MEO Design & Communication, meomeo.ch, 2016.
7. A. K. Singh, R. Gupta, A. Ghosh, and A. Misra, “Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations,” Diabetes Metab. Syndr. Clin. Res. Rev., vol. 14, no. 4, pp. 303–310, 2020, doi: 10.1016/j.dsx.2020.04.004.
8. Z. Wu and J. M. McGoogan, “Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China,” Jama, pp. 1239–1242, 2020, doi: 10.1001/jama.2020.2648.
9. P. Singh, Y. J. Kim, D. Zhang, and D. C. Yang, “Biological Synthesis of Nanoparticles from Plants and Microorganisms,” Trends Biotechnol., vol. 34, no. 7, pp. 588–599, 2016, doi: 10.1016/j.tibtech.2016.02.006.
10. M. Bachelet, “Design of pH-responsive gold nanoparticles in oncology,” Mater. Sci. Technol., vol. 32, no. 8, pp. 794–804, 2016, doi: 10.1179/1743284715Y.0000000090.
11. T. Taufikurohmah, I. G. M. Sanjaya, A. Baktir, and A. Syahrani, “Activity Test of Nanogold for Reduction of Free Radicals, a Pre-Assessment Utilisation Nanogold in Pharmaceutical as Medicines and Cosmetics,” J. Mater. Sci. Eng. B, vol. 2, no. 12, pp. 611–617, 2012.
12. M. A. Syed and S. H. A. Bukhari, “Gold Nanoparticle Based Microbial Detection and Identification Muhammad,” J. Biomed. Nanotechnol., vol. 7, no. 2, pp. 1–9, 2011, doi: 10.1166/jbn.2011.1281.
13. S. R. Ahmed, J. Kim, T. Suzuki, J. Lee, and E. Y. Park, “Detection of Influenza Virus Using Peroxidase-mimic of Gold Nanoparticles†,” Biotechnol. Bioeng., pp. 1–19, 2016, doi: 10.1002/bit.25982.
14. T. Taufikurohmah, D. Winarni, A. Baktir, I. G. M. Sanjaya, and A. Syahrani, “Histology Study: Pre-Clinic Test of Nanogold in Mus Musculus Skin , at Fibroblast Proliferation and Collagen Biosynthesis,” Chem. Mater. Res., vol. 3, no. 5, pp. 55–60, 2013.
15. L. A. Dykman and N. G. Khlebtsov, “Gold Nanoparticles in Biology and Medicine: Recent Advances and Prospects,” Acta Naturae, vol. 3, no. 2, pp. 34–55, Jun. 2011, doi: 10.32607/20758251-2011-3-2-34-55.
16. J. K. Schluesener and H. J. Schluesener, “Nanosilver: Application and novel aspects of toxicology,” Arch. Toxicol., vol. 87, no. 4, pp. 569–576, 2013, doi: 10.1007/s00204-012-1007-z.
17. A. Hebeish, M. H. El-Rafie, M. A. El-Sheikh, and M. E. El-Naggar, “Nanostructural Features of Silver Nanoparticles Powder Synthesised through Concurrent Formation of the Nanosized Particles of Both Starch and Silver,” J. Nanotechnol., pp. 1–10, 2013, doi: 10.1155/2013/201057.
18. J. L. Elechiguerra et al., “Interaction of silver nanoparticles with HIV-1,” J. Nanobiotechnology, vol. 3, no. 6, pp. 1–10,
2005, doi: 10.1186/1477-3155-3-6.
19. S. BarathManiKanth et al., “Anti-oxidant effect of gold nanoparticles restrains hyperglycemic conditions in diabetic mice,” J. Nanobiotechnology, vol. 8, no. July 2010, 2010, doi: 10.1186/1477-3155-8-16.
20. T. I. Shaheen et al., “Anti-diabetic assessment ; in vivo study of gold and core-shell silver-gold nanoparticles on streptozotocin-induced diabetic rats,” Biomed. Pharmacother., vol. 83, pp. 865–875, 2016,
doi: 10.1016/j.biopha.2016.07.052.
21. B. A. Katsnelson et al., “Comparative in Vivo Assessment of Some Adverse Bioeffects of Equidimensional Gold and Silver Nanoparticles and the Attenuation of Nanosilver’s Effects with a Complex of Innocuous Bioprotectors,” Int. J. Mol. Sci., vol. 14, pp. 2449–2483, 2013, doi: 10.3390/ijms14022449.
22. Y. H. Choi and H. K. Han, “Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics,” J. Pharm. Investig., vol. 48, pp. 43–60, 2018, doi: 10.1007/s40005-017-0370-4.
23. L. Dyshlyuk, O. Babich, S. Ivanova, N. Vasilchenco, A. Prosekov, and S. Sukhikh, “Suspensions of metal nanoparticles as a basis for protection of internal surfaces of building structures from biodegradation,” Case Stud. Constr. Mater., vol. 12, pp. 1–8, 2020, doi: 10.1016/j.cscm.2019.e00319.
24. H. Li and L. Rothberg, “Colorimetric detection of DNA sequences based on electrostatic interactions with unmodified gold nanoparticles,” in Proceedings of the National Academy of Sciences of the United States of America, 2004, vol. 101, no. 39, pp. 14036–14039, doi: 10.1073/pnas.0406115101.
25. S. F. Ahmed, A. A. Quadeer, and M. R. McKay, “Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies Syed,” Viruses, vol. 12, no. 3, 2020, doi: 10.3390/v12030254.
26. S. Galdiero, A. Falanga, M. Vitiello, M. Cantisani, V. Marra, and M. Galdiero, “Silver Nanoparticles as Potential Antiviral Agents,” Molecules, vol. 16, pp. 8894–8918, 2011, doi: 10.3390/molecules16108894.
27. S. S. Jeremiah, K. Miyakawa, T. Morita, Y. Yamaoka, and A. Ryo, “Potent antiviral effect of silver nanoparticles on SARS-CoV-2,” Biochem. Biophys. Res. Commun., vol. 533, no. 1, pp. 195–200, Nov. 2020, doi: 10.1016/j.bbrc.2020.09.018.
28. B. Nowack, H. F. Krug, and M. Height, “120 Years of Nanosilver History: Implications for Policy Makers,” Environ. Sci. Technol., vol. 45, pp. 7593–7595, 2011, doi: 10.1021/es2017895.
29. R. Singla, S. Soni, V. Patial, and P. M. Kulurkar, “Cytocompatible Anti-microbial Dressings of S yzygium cumini Cellulose Nanocrystals Decorated with Silver Nanoparticles Accelerate Acute and Diabetic Wound Healing,” Sci. Rep., vol. 7, no. 10457, pp. 1–13, 2017, doi: 10.1038/s41598-017-08897-9.
30. V. Vijayakumar, S. K. Samal, S. Mohanty, and S. K. Nayak, “Recent Advancements in Biopolymer and Metal Nanoparticle-Based Materials in Diabetic Wound Healing Management,” Int. J. Biol. Macromol., vol. 122, pp. 1–52, 2018, doi: 10.1016/j.ijbiomac.2018.10.120.
31. Pemerintah Kota Surabaya, “Surabaya Lawan COVID-19,” 2021. [Online]. Available:
https://lawancovid-19.surabaya.go.id/visualisasi/graph. [Accessed: 12-Jan-2021].
32. A. A. Dayem et al., “The Role of Reactive Oxygen Species (ROS) in the Biological Activities of Metallic Nanoparticles,” Int. J. Mol. Sci., vol. 18, pp. 1–21, 2017, doi: 10.3390/ijms18010120.
33. A. Majdalawieh, M. C. Kanan, O. El-Kadri, and S. M. Kanan, “Recent Advances in Gold and Silver Nanoparticles: Synthesis and Applications,” J. Nanosci. Nanotechnol., vol. 14, pp. 4757–4780, 2014, doi: 10.1166/jnn.2014.9526.
34. R. Opris et al., “THE EFFECT OF SAMBUCUS NIGRA L. EXTRACT AND PHYTOSINTHESIZED GOLD NANOPARTICLES ON DIABETIC RATS,” Colloids Surfaces B Biointerfaces, vol. 150, pp. 192–200, 2017,
doi: 10.1016/j.colsurfb.2016.11.033.
35. P. Ghosh, G. Han, M. De, C. K. Kim, and V. M. Rotello, “Gold nanoparticles in delivery applications,” Adv. Drug Deliv. Rev., vol. 60, no. 11, pp. 1307–1315, 2008, doi: 10.1016/j.addr.2008.03.016.
36. G. K. Ferreira et al., “Gold nanoparticles alter parameters of oxidative stress and energy metabolism in organs of adult rats,” Biochem Cell Biol, vol. 93, no. 6, pp. 548–557, 2015, doi: http://dx.doi.org/10.1139/bcb-2015-0030.
37. M. Sengani and D. R. V, “Identification of Potential Anti-oxidant Indices by Biogenic Gold Nanoparticles in Hyperglycemic Wistar Rats,” Environ. Toxicol. Pharmacol., 2017, doi: 10.1016/j.etap.2017.01.007.
38. M. Wang, S. K. Marepally, P. K. Vemula, and C. Xu, “Inorganic Nanoparticles for Transdermal Drug Delivery and Topical Application,” Nanosci. Dermatology, pp. 57–72, 2016, doi: 10.1016/B978-0-12-802926-8.00005-7.
39. S. Roy, S. Shankar, and J. Rhim, “Melanin-mediated synthesis of silver nanoparticle and its use for the preparation of carrageenan-based anti-bacterial films,” Food Hydrocoll., pp. 1–43, 2018, doi: 10.1016/j.foodhyd.2018.10.013.
40. A.-C. Burdusel, O. Gherasim, A. M. Grumezescu, L. Mogoantă, A. Ficai, and E. Andronescu, “Biomedical Applications of Silver Nanoparticles : An Up-to-Date Overview,” nanomaterials, vol. 8, no. 681, pp. 1–25, 2018,
doi: 10.3390/nano8090681.
41. S. Hamdan et al., “Nanotechnology-Driven Therapeutic Interventions in Wound Healing: Potential Uses and Applications,” ACS Cent. Sci., vol. 3, pp. 163–175, 2017, doi: 10.1021/acscentsci.6b00371.
42. A. Sengottaiyan et al., “Synthesis and characterisation of Solanum nigrum -mediated silver nanoparticles and its protective effect on alloxan-induced diabetic rats,” J. Nanostructure Chem., vol. 6, pp. 41–48, 2016, doi: 10.1007/s40097-015-0178-6.
43. H. Agarwal, S. V. Kumar, and S. Rajeshkumar, “ANTI-DIABETIC EFFECT OF SILVER NANOPARTICLES SYNTHESISED USING LEMONGRASS ( CYMBOPOGON CITRATUS ) THROUGH CONVENTIONAL HEATING AND MICROWAVE IRRADIATION APPROACH,” J. Microbiol. Biotechnol. Food Sci., vol. 7, no. 4, pp. 371–376, 2018, doi: 10.15414/jmbfs.2018.7.4.371-376.
44. A. Badawi and S. G. Ryoo, “Prevalence of diabetes in the 2009 influenza A (H1N1) and the middle east respiratory syndrome coronavirus: A systematic review and meta-analysis,” J. Public health Res., vol. 5, no. 733, pp. 130–138, 2016, doi: 10.4081/jphr.2016.733.
45. R. Muniyappa and S. Gubbi, “COVID-19 pandemic, coronaviruses, and diabetes mellitus,” Am. J. Physiol. – Endocrinol. Metab., vol. 318, no. 5, pp. E736–E741, 2020, doi: 10.1152/ajpendo.00124.2020.
46. D. Ardigo, S. Valtuena, I. Zavaroni, M. C. Baroni, and R. Delsignore, “Pulmonary Complications in Diabetes Mellitus: The Role of Glycemic Control,” Curr. Drug Targets Inflamm. Allergy, vol. 3, pp. 455–458, 2004,
doi: 10.2174/1568010042634488.
47. L. Fuso, D. Pitocco, and R. Antonelli‐Incalzi, “Diabetic lung, an underrated complication from restrictive functional pattern to pulmonary hypertension,” Diabetes Metab Res Rev, 2019, doi: 10.1002/dmrr.3159.
48. S. Costantino et al., “Impact of Glycemic Variability on Chromatin Remodeling, Oxidative Stres , and Endothelial Dysfunction in Patients With Type 2 Diabetes and With Target HbA 1c Levels,” Diabetes, vol. 66, pp. 2472–2482, 2017, doi: https://doi.org/10.2337/db17-0294.
49. I. A. A. El-azeem, G. Hamdy, M. Amin, and A. Rashad, “Pulmonary function changes in diabetic lung,” Egypt. J. Chest Dis. Tuberc., vol. 62, pp. 513–517, 2013, doi: 10.1016/j.ejcdt.2013.07.006.
50. B. J. Philips, J.-X. Meguer, J. Redman, and E. H. Baker, “Factors determining the appearance of glucose in upper and lower respiratory tract secretions,” Intensive Care Med, vol. 29, pp. 2204–2210, 2003, doi: 10.1007/s00134-003-1961-2.
51. A. Iqbal et al., “Effect of Hypoglycemia on Inflammatory Responses and the Response to Low-Dose Endotoxemia in Humans,” J. Clin. Endocrinol. Metab., vol. 104, no. 4, pp. 1187–1199, 2019, doi: 10.1210/jc.2018-01168.
52. R. Rodriguez-gutierrez, J. G. Gonzalez-gonzalez, J. A. Zuñiga-hernandez, and R. G. Mccoy, “Benefits and harms of intensive glycemic control in patients with type 2 diabetes,” BMJ, vol. 367, 2019, doi: 10.1136/bmj.l5887.
53. R. Pal and A. Bhansali, “COVID-19, diabetes mellitus and ACE2: The conundrum,” Diabetes Res. Clin. Pract., vol. 162, pp. 1–3, 2020, doi: 10.1016/j.diabres.2020.108132.
54. S. M. Bindom and E. Lazartigues, “The sweeter side of ACE2: Physiological evidence for a role in diabetes,” Mol. Cell. Endocrinol., vol. 302, pp. 193–202, 2009, doi: 10.1016/j.mce.2008.09.020.
55. D. Wrapp et al., “Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation,” Science (80-. )., vol. 367, pp. 1260–1263, 2020, doi: 10.1126/science.aax0902.
56. H. Xu et al., “High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa,” Int. J. Oral Sci., vol. 12, no. 8, pp. 1–5, 2020, doi: 10.1038/s41368-020-0074-x.